Your browser doesn't support javascript.
loading
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany, Leila M; LaPorte, Sherry L; Wong, Laurie; White, Clayton; Vinod, Veena; Shen, Joel; Yu, Wendy; Koditek, David; Winter, Michael B; Moore, Stephen J; Mei, Li; Diep, Linnea; Huang, Yuanhui; Liu, Shouchun; Vasiljeva, Olga; West, Jim; Richardson, Jennifer; Irving, Bryan; Belvin, Marcia; Kavanaugh, W Michael.
Afiliación
  • Boustany LM; CytomX Therapeutics, Inc, South San Francisco, California.
  • LaPorte SL; CytomX Therapeutics, Inc, South San Francisco, California.
  • Wong L; CytomX Therapeutics, Inc, South San Francisco, California.
  • White C; CytomX Therapeutics, Inc, South San Francisco, California.
  • Vinod V; CytomX Therapeutics, Inc, South San Francisco, California.
  • Shen J; CytomX Therapeutics, Inc, South San Francisco, California.
  • Yu W; CytomX Therapeutics, Inc, South San Francisco, California.
  • Koditek D; CytomX Therapeutics, Inc, South San Francisco, California.
  • Moore SJ; CytomX Therapeutics, Inc, South San Francisco, California.
  • Mei L; CytomX Therapeutics, Inc, South San Francisco, California.
  • Diep L; CytomX Therapeutics, Inc, South San Francisco, California.
  • Liu S; CytomX Therapeutics, Inc, South San Francisco, California.
  • Vasiljeva O; CytomX Therapeutics, Inc, South San Francisco, California.
  • West J; CytomX Therapeutics, Inc, South San Francisco, California.
  • Richardson J; CytomX Therapeutics, Inc, South San Francisco, California.
  • Irving B; CytomX Therapeutics, Inc, South San Francisco, California.
  • Belvin M; CytomX Therapeutics, Inc, South San Francisco, California.
  • Kavanaugh WM; CytomX Therapeutics, Inc, South San Francisco, California.
Cancer Res ; 82(22): 4288-4298, 2022 11 15.
Article en En | MEDLINE | ID: mdl-36112781
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo CD3 / Neoplasias del Colon / Anticuerpos Biespecíficos / Receptores ErbB Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo CD3 / Neoplasias del Colon / Anticuerpos Biespecíficos / Receptores ErbB Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2022 Tipo del documento: Article